Connect® MM- The Multiple Myeloma Disease Registry

Celgene3,011 enrolled

Overview

The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients.

Study Type

OBSERVATIONAL

Enrollment

3,011

Conditions

Multiple Myeloma

Interventions

First-line therapyOTHER

As prescribed by treating physician

Second-line Multiple Myeloma treatmentsDRUG

As prescribed by the treating physician

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Cohort 1 and 2 * Newly diagnosed with symptomatic MM within 2 months of enrollment in Connect® MM registry * Age ≥18 years * Willing and able to provide signed informed consent * Agrees to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel Cohort 3 * Received 1L therapy for symptomatic active MM and subsequently has evidence of disease progression. Prior 1L MM treatment received, including anti-myeloma therapy, transplant, chemotherapy, radiation, and surgery, must be known. * Initiated or intends to initiate 2L systemic therapy for MM after the first documented relapsed/refractory date (i.e. 1L PD). * Enrollment date must be within 90 days of start date (or intended start date) of 2L systemic therapy. Exclusion Criteria: Cohort 1 and 2 \- None Cohort 3 * Patient's 1L MM treatment was for smoldering MM or MGUS, and not for symptomatic MM * Currently active in any MM Registry, including but not limited to, the Connect® MM registry or another Celgene/BMS-Sponsored registry. * Patients who have discontinued from Connect® MM or another Celgene/BMS-Sponsored registry could be considered for enrollment in Cohort 3, if inclusion and exclusion criteria are met. * Currently enrolled or intending to enroll within 90 days in any interventional clinical trial in which any treatment is an investigational product that cannot be identified

Locations (253)

Outcomes

Primary Outcomes

Participant baseline demographics

Time frame: Baseline

Participant medical history

Time frame: Baseline

Participant Multiple Myeloma diagnosis information

Time frame: Baseline

Participant Multiple Myeloma treatment history

Time frame: Baseline

Multiple Myeloma-related supportive concomitant medications and procedures

Time frame: Baseline, every 3-months up to 5 years (Cohort 3), or up to 16 years (Cohort 1 & 2), or date of early discontinuation

Occurance of second primary malignancy

Time frame: Baseline, every 3-months up to 5 years (Cohort 3), or up to 16 years (Cohort 1 & 2), or date of early discontinuation

Number of participants enrolled in a clinical trial

Cohort 1 and 2 only

Time frame: Baseline, every 3-months up to 16 years or date of early discontinuation

Lines of therapy prescribed

Time frame: Baseline, every 3-months up to 5 years (Cohort 3), or up to 16 years (Cohort 1 & 2), or date of early discontinuation

Participant disease response assessment results

Time frame: Baseline, every 3-months up to 5 years (Cohort 3), or up to 16 years (Cohort 1 & 2), or date of early discontinuation

Secondary Outcomes

Participant socioeconomic status

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

The Cancer Center of Huntsville

Huntsville, Alabama, United States

DCH Health System

Tuscaloosa, Alabama, United States

US Oncology - Arizona Oncology Associates - Rudasill

Tucson, Arizona, United States

St. Edward Mercy Medical Center

Fort Smith, Arkansas, United States

Genesis Cancer Center

Hot Springs, Arkansas, United States

Clopton Clinic Hematology/Oncology

Jonesboro, Arkansas, United States

Little Rock Hematology Oncology Associates, PA

Little Rock, Arkansas, United States

Pacific Cancer Medical Center, Inc

Anaheim, California, United States

Alta Bates Summit Comprehensive Cancer Center

Berkeley, California, United States

Southbay Oncology Hematology Partners

Campbell, California, United States

...and 243 more locations

Time frame: Baseline

Participant EuroQol-5 Dimensions (EQ-5D) questionnaire results

Time frame: Baseline, every 3-months up to 5 years (Cohort 3) or up to 16 years (Cohort 1 and 2), or date of early discontinuation

Participant Functional Assessment of Cancer Therapy - Multiple Myeloma (FACT-MM) questionnaire results

Time frame: Baseline, every 3-months up to 5 years (Cohort 3) or up to 16 years (Cohort 1 and 2), or date of early discontinuation

Participant Visual Analogue Score (VAS) questionnaire results

Time frame: Baseline, every 3-months up to 5 years (Cohort 3) or up to 16 years (Cohort 1 and 2), or date of early discontinuation

Participant participant survival status

Time frame: Every 3-months up to 5 years (Cohort 3) or up to 16 years (Cohort 1 and 2), or date of early discontinuation

Participant participant Adverse Events (AEs)

Time frame: Every 3-months up to 5 years (Cohort 3) or up to 16 years (Cohort 1 and 2) or date of early discontinuation

Reason for registry discontinuation

Time frame: Date of early discontinuation assessed up to 5 years (Cohort 3) or up to 16 years (Cohort 1 and 2)

Reason for treatment initiation or discontinuation

Cohort 3 only